DiaMedica Therapeutics Inc.

NasdaqCM:DMAC Stock Report

Market Cap: US$113.9m

DiaMedica Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

DiaMedica Therapeutics has a total shareholder equity of $51.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $54.2M and $3.1M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$52.90m
EquityUS$51.06m
Total liabilitiesUS$3.10m
Total assetsUS$54.16m

Recent financial health updates

Recent updates

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

May 16
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 12
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold

Jul 06

We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

Jun 16
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 04
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.

Nov 05

DiaMedica: Undercovered Stroke Drug Company With Decent Data

Jun 13

We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

May 01
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

Feb 13
Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

Jan 09
We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Financial Position Analysis

Short Term Liabilities: DMAC's short term assets ($53.7M) exceed its short term liabilities ($2.8M).

Long Term Liabilities: DMAC's short term assets ($53.7M) exceed its long term liabilities ($317.0K).


Debt to Equity History and Analysis

Debt Level: DMAC is debt free.

Reducing Debt: DMAC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DMAC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: DMAC has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 20.1% each year.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.